These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 28667354

  • 21. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
    Iwamoto K, Ishihara H, Takagi T, Kondo T, Yoshida K, Iizuka J, Tanabe K.
    Med Oncol; 2018 Apr 23; 35(6):78. PubMed ID: 29687160
    [Abstract] [Full Text] [Related]

  • 22. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
    Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI.
    J Clin Oncol; 2017 Jun 01; 35(16):1764-1769. PubMed ID: 28113029
    [Abstract] [Full Text] [Related]

  • 23. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.
    BJU Int; 2016 Jan 01; 117(1):110-7. PubMed ID: 25252180
    [Abstract] [Full Text] [Related]

  • 24. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C, Imarisio I, Ganini C, Morbini P, Vercelli A, Bregant C, Porta C.
    Future Oncol; 2012 Dec 01; 8(12):1605-12. PubMed ID: 23231522
    [Abstract] [Full Text] [Related]

  • 25. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
    Togo Y, Shimatani K, Hanasaki T, Yo T, Nakanishi Y, Nagasawa S, Hashimoto T, Shiraishi Y, Taoka R, Suzuki T, Go S, Higuchi Y, Kanematsu A, Nojima M, Tsuchihashi K, Makino Y, Shimizu Y, Kanamaru S, Kono Y, Matsumoto K, Utsunomiya N, Ito N, Kawakita M, Yamamoto S.
    Hinyokika Kiyo; 2014 May 01; 60(5):209-14. PubMed ID: 24894855
    [Abstract] [Full Text] [Related]

  • 26. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
    Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, Lerut E, Karadimou A, Couchy G, Sebe P, Ravaud A, Zerbib M, Caty A, Paridaens R, Schöffski P, Verkarre V, Berger J, Patard JJ, Zucman-Rossi J, Oudard S.
    Acta Oncol; 2014 Oct 01; 53(10):1413-22. PubMed ID: 24874929
    [Abstract] [Full Text] [Related]

  • 27. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
    Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R.
    Drugs R D; 2017 Dec 01; 17(4):585-596. PubMed ID: 28895069
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
    Zhang CJ, Zhao PJ, Li XS, Zhao J, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, He ZS, Jin J, Zhou LQ.
    Chin Med J (Engl); 2013 Dec 01; 126(15):2826-9. PubMed ID: 23924450
    [Abstract] [Full Text] [Related]

  • 29. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.
    Maráz A, Cserháti A, Uhercsák G, Szilágyi É, Varga Z, Révész J, Kószó R, Varga L, Kahán Z.
    BMC Cancer; 2018 Mar 15; 18(1):296. PubMed ID: 29544452
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma.
    Maruzzo M, Basso U, Diminutto A, Roma A, Zustovich F, Brunello A, Fiduccia P, Banzato A, Zattoni F, Zagonel V.
    Future Oncol; 2016 Apr 15; 12(7):909-19. PubMed ID: 26883094
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.
    Eur Urol; 2011 Sep 15; 60(3):448-54. PubMed ID: 21612860
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
    Neri B, Vannini A, Brugia M, Muto A, Rangan S, Rediti M, Tassi R, Cerullo C.
    Int J Urol; 2013 May 15; 20(5):478-83. PubMed ID: 23113655
    [Abstract] [Full Text] [Related]

  • 39. Sunitinib in kidney cancer: 10 years of experience and development.
    Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S.
    Expert Rev Anticancer Ther; 2017 Feb 15; 17(2):129-142. PubMed ID: 27967249
    [Abstract] [Full Text] [Related]

  • 40. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
    Neri B, Vannini A, Tassi R, Brugia M, Rangan S, Rediti M, Cerullo C.
    Oncol Res; 2012 Feb 15; 20(5-6):259-64. PubMed ID: 23581233
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.